Insight Molecular Diagnostics Inc. (IMDX) vs NRx Pharmaceuticals, Inc. (NRXP)
A side-by-side comparison of Insight Molecular Diagnostics Inc. and NRx Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IMDX
Insight Molecular Diagnostics Inc.
$3.42HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
NRXP
NRx Pharmaceuticals, Inc.
$2.89HealthcareDelayed quote: Oct 6, 2026, 11:59 AM EDT
Total return — IMDX vs NRXP
growth of $100 · dividends reinvested · last 9yIMDX -96.5% (-31.0%/yr)NRXP -97.0% (-32.3%/yr)IMDX compounded faster over this window
IMDX NRXP
IMDX vs NRXP: by the numbers
- •NRXP is the larger company ($125M vs $110M market cap).
- •Both run net losses; NRXP's is the smaller (-691.81% vs -2955.63% net margin).
Metrics side by side
Valuation
| Metric | IMDX | NRXP |
|---|---|---|
| P/S ratio | 66.13 | 36.80 |
Profitability
| Metric | IMDX | NRXP |
|---|---|---|
| Gross margin | 11.17% | 58.78% |
| Operating margin | -754.08% | -1324.41% |
| Net margin | -2955.63% | -691.81% |
| ROIC | -223.06% | N/A |
Growth (annualized)
| Metric | IMDX | NRXP |
|---|---|---|
| Revenue CAGR (5Y) | 27.24% | N/A |
| Total return CAGR (5Y) | -44.39% | -49.61% |
Frequently asked
- How have IMDX and NRXP total returns compared?
- Over the past 5 years, IMDX delivered -44.39% and NRXP delivered -49.61% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Insight Molecular Diagnostics ROENRx Pharmaceuticals ROEInsight Molecular Diagnostics operating marginNRx Pharmaceuticals operating marginInsight Molecular Diagnostics revenue growthNRx Pharmaceuticals revenue growthInsight Molecular Diagnostics free cash flowNRx Pharmaceuticals free cash flow
Insight Molecular Diagnostics & NRx Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.